Back to Journals » Neurobehavioral HIV Medicine » Volume 5

Apolipoprotein-E genotype and human immunodeficiency virus-associated neurocognitive disorder: the modulating effects of older age and disease severity

Authors Panos SE, Hinkin CH, Singer EJ, Thames AD, Patel SM, Sinsheimer JS, Del Re AC, Gelman BB, Morgello S, Moore DJ, Levine AJ

Received 25 October 2012

Accepted for publication 24 December 2012

Published 19 June 2013 Volume 2013:5 Pages 11—22

DOI https://doi.org/10.2147/NBHIV.S39573

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Stella E Panos,1,2 Charles H Hinkin,1,2 Elyse J Singer,3 April D Thames,1,2 Sapna M Patel,1,2 Janet S Sinsheimer,4 AC Del Re,5 Benjamin B Gelman,6 Susan Morgello,7 David J Moore,8 Andrew J Levine3

1Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, David Geffen School of Medicine, 2VA Greater Los Angeles Healthcare System; 3National Neurological AIDS Bank, UCLA Department of Neurology, 4Departments of Biomathematics and Human Genetics, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 5Department of Psychiatry, Stanford University, Menlo Park, CA, 6Department of Pathology, University of Texas Medical Branch, Galveston, TX, 7Departments of Neurology, Neuroscience, and Pathology, The Mount Sinai School of Medicine, New York, NY, 8Department of Psychiatry, School of Medicine, University of California San Diego, La Jolla, CA, USA

Background: The apolipoprotein-E (APOE) ε4 allele is a risk factor for vascular dementia and Alzheimer’s disease. Recent studies are equivocal with regards to whether or not the ε4 allele confers increased risk for the development of human immunodeficiency virus (HIV)-associated neurocognitive disorder (HAND), but suggest that age and/or disease severity may be modulating factors. The aim of this study was to assess the interactions and contributions of APOE genotype, age, and HIV disease severity as risk factors for HAND in HIV-infected adults.
Methods: Participants were 259 HIV-positive individuals who underwent APOE genotyping, a standardized neurological evaluation, a comprehensive neuropsychological evaluation, and laboratory testing.
Results: Older ε4 carriers showed a higher frequency of HAND compared with age-matched non-ε4 carriers. Analysis by discrete neurocognitive domain revealed that advanced age modulated the effect of the ε4 allele, such that older ε4 allele carriers showed reduced executive functioning and information processing speed. Exploratory analyses assessing the relationship between ε4 and disease severity in the overall sample revealed that disease severity modulated the effect of the ε4 allele on cognition. Lower absolute CD4+ cell count among ε4 allele carriers was associated with poorer working memory ability.
Conclusion: Advancing age and degree of immunosuppression may influence the association between APOE ε4 allele status and HAND. These two factors need to be taken into account in future research.

Keywords: apolipoprotein-E, human immunodeficiency virus, aging, neurocognition

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Emerging and future therapies for hemophilia

Carr ME, Tortella BJ

Journal of Blood Medicine 2015, 6:245-255

Published Date: 3 September 2015

Acquired hemophilia A: emerging treatment options

Janbain M, Leissinger CA, Kruse-Jarres R

Journal of Blood Medicine 2015, 6:143-150

Published Date: 8 May 2015

A new recombinant factor VIII: from genetics to clinical use

Santagostino E

Drug Design, Development and Therapy 2014, 8:2507-2515

Published Date: 12 December 2014

Second case report of successful electroconvulsive therapy for a patient with schizophrenia and severe hemophilia A

Saito N, Shioda K, Nisijima K, Kobayashi T, Kato S

Neuropsychiatric Disease and Treatment 2014, 10:865-867

Published Date: 16 May 2014

Managing hemophilia: the role of mobile technology

Khair K, Holland M

Smart Homecare Technology and TeleHealth 2014, 2:39-44

Published Date: 6 May 2014

Rituximab for managing acquired hemophilia A in a case of chronic neutrophilic leukemia with the JAK2 kinase V617F mutation

Imashuku S, Kudo N, Kubo K, Saigo K, Okuno N, Tohyama K

Journal of Blood Medicine 2012, 3:157-161

Published Date: 5 December 2012

The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia

Rivka Yatuv, Micah Robinson, Inbal Dayan-Tarshish, et al

International Journal of Nanomedicine 2010, 5:581-591

Published Date: 6 August 2010